Doxazosin was not teratogenic in animal studies. At doses 300 times the maximum recommended human dose, the fetal survival rate decreased. Doxazosin was accumulated in the milk of dams.
Safety for use in pregnancy has not been established.
The risk to the fetus cannot be excluded. Pregnant women may be given Kamiren XL only if it is clearly needed, when the potential benefit for the mother justifies the risk to the fetus.
Breastfeeding is not recommended during the treatment because safety for the infant has not been established.